Prothena Corporation plc Ordinary Shares (PRTA) Dividend History

Prothena Corporation plc is a biotechnology company focused on developing therapies for neurodegenerative and rare diseases. Founded in 2012 and headquartered in Dublin, Ireland, it leverages its expertise in immunology and protein biology to create innovative treatments, primarily targeting conditions such as Alzheimer's disease, Parkinson's disease, and other amyloid-related disorders. The company's approach often involves antibody discovery, molecular engineering, and collaboration with partners to advance its drug pipeline.

77 Sir John Rogerson'S Quay, Block C, Dublin 2, L2, D02 VK60
Phone: 011-353-1-236-2500
Website: https://www.prothena.com

Dividend History

Prothena Corporation plc Ordinary Shares currently does not pay dividends

Company News

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.

GlobeNewswire Inc.
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.

GlobeNewswire Inc.

Featured Companies: ABBV ANVS DNLI PMN
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

Prothena's Parkinson's drug prasinezumab, partnered with Roche, missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses.

Benzinga
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

The rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.

GlobeNewswire Inc.

Featured Companies: IONS VYGR
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research

Featured Companies: ALEC

Dividend data last updated 06/07/2025 06:16:08 UTC